Evidence map›Paper›PMID 42773792›Full record

ReviewEmerging microbes & infections2026

Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam.

Junxin Zhou, Rui Weng, Yining Ye, Xinhong Han, Huangdu Hu, Wenzeng Xu, Qiucheng Shi, Yinping Wang, Weiyi Huang, Jingjing Quan and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Junxin ZhouDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Rui WengDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yining YeDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Xinhong HanDepartment of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
Huangdu HuDepartment of Infectious Diseases, Centre for General Practice Medicine, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Wenzeng XuDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Qiucheng ShiDepartment of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yinping WangDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Weiyi HuangDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Jingjing QuanDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Ping ZhangDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Ying FuDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Jintao HeCentre of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Zhihui ZhouDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Xiaoxing DuDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Dongdong ZhaoDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yan JiangDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yunsong YuDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant Gram-negative bacteria pose a significant threat to global public health, with resistance mediated by metallo-β-lactamases being particularly prominent. Aztreonam/avibactam (AZA), a novel β-lactam/β-lactamase inhibitor combination, had been approved in China and the European Union for treating complicated intra-abdominal infections and hospital-acquired pneumonia (including ventilator-associated pneumonia) in adults. The combination exhibits broad-spectrum antimicrobial activity against carbapenemase-producing

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesGram-Negative BacteriaBacterial ProteinsDrug CombinationsDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesDrug CombinationsAztreonam/avibactamBLBLIsMBLsPBP3 insertionPK/PD

Identifiers

PMID42773792
PMCPMC13618160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.